Inclisiran til hyperkolesterolæmi

Nerma Todorovac; Michael Skov Hansen; Frank-Peter Elpert

doi:10.61409/V12230767

Inclisiran til hyperkolesterolæmi

Translated title of the contribution: Hypercholesterolaemia treated with inclisiran

Nerma Todorovac^*, Michael Skov Hansen, Frank-Peter Elpert

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

10 Downloads (Pure)

Abstract

In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects. In 2021, the patient received inclisiran therapy, the first known instance of its application in Denmark. No side effects were reported, and LDL cholesterol levels were significantly reduced. This case report highlights the potential of inclisiran as an effective and well-tolerated treatment for individuals with heterozygous FH.

Translated title of the contribution	Hypercholesterolaemia treated with inclisiran
Original language	Danish
Article number	V12230767
Journal	Ugeskrift for Læger
Volume	186
Issue number	19
ISSN	0041-5782
DOIs	https://doi.org/10.61409/V12230767
Publication status	Published - 30. Sept 2024

Documents & Links

10.61409/V12230767Licence: CC BY-NC-ND

Open Access VersionFinal published version, 49 KBLicence: CC BY-NC-ND

Cite this

@article{35d7f6c1e13745d7b60f5e2c3440a928,

title = "Inclisiran til hyperkolesterol{\ae}mi",

abstract = "In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects. In 2021, the patient received inclisiran therapy, the first known instance of its application in Denmark. No side effects were reported, and LDL cholesterol levels were significantly reduced. This case report highlights the potential of inclisiran as an effective and well-tolerated treatment for individuals with heterozygous FH.",

keywords = "Adult, Anticholesteremic Agents/therapeutic use, Cholesterol, LDL/blood, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Hyperlipoproteinemia Type II/drug therapy, PCSK9 Inhibitors",

author = "Nerma Todorovac and Hansen, {Michael Skov} and Frank-Peter Elpert",

year = "2024",

month = sep,

day = "30",

doi = "10.61409/V12230767",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "19",

}

TY - JOUR

T1 - Inclisiran til hyperkolesterolæmi

AU - Todorovac, Nerma

AU - Hansen, Michael Skov

AU - Elpert, Frank-Peter

PY - 2024/9/30

Y1 - 2024/9/30

N2 - In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects. In 2021, the patient received inclisiran therapy, the first known instance of its application in Denmark. No side effects were reported, and LDL cholesterol levels were significantly reduced. This case report highlights the potential of inclisiran as an effective and well-tolerated treatment for individuals with heterozygous FH.

AB - In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects. In 2021, the patient received inclisiran therapy, the first known instance of its application in Denmark. No side effects were reported, and LDL cholesterol levels were significantly reduced. This case report highlights the potential of inclisiran as an effective and well-tolerated treatment for individuals with heterozygous FH.

KW - Adult

KW - Anticholesteremic Agents/therapeutic use

KW - Cholesterol, LDL/blood

KW - Female

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use

KW - Hyperlipoproteinemia Type II/drug therapy

KW - PCSK9 Inhibitors

U2 - 10.61409/V12230767

DO - 10.61409/V12230767

M3 - Tidsskriftartikel

C2 - 38903035

SN - 0041-5782

VL - 186

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 19

M1 - V12230767

ER -

Inclisiran til hyperkolesterolæmi

Abstract

Documents & Links

Fingerprint

Cite this